Research programme: sirtuin activators - Sirtris

Drug Profile

Research programme: sirtuin activators - Sirtris

Alternative Names: SRT 1720; SRT 2172; SRT2183

Latest Information Update: 22 Dec 2009

Price : $50

At a glance

  • Originator Sirtris Pharmaceuticals
  • Developer Sirtris
  • Class Small molecules
  • Mechanism of Action SIRT1 protein stimulants; Sirtuin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Cancer; Chronic obstructive pulmonary disease; Huntington's disease; Inflammation; Neurological disorders; Type 2 diabetes mellitus

Most Recent Events

  • 22 Dec 2009 Study information from a preclinical trial of some SIRT1 activators presented at the 51st Annual Meeting and Exposition of the American Society of Hematology, New Orleans (ASH-2009)
  • 17 Sep 2008 Sirtris exclusively licenses SIRT3-based intellectual property from Harvard University
  • 06 Jun 2008 Sirtris Pharmaceuticals has been acquired by GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top